AAAAAA

   
Results: 1-12 |
Results: 12
Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study
Authors: Garufi, C Nistico, C Brienza, S Vaccaro, A D'Ottavio, A Zappala, AR Aschelter, AM Terzoli, E
Citation: C. Garufi et al., Single-agent oxaliplatin in pretreated advanced breast cancer patients: A phase II study, ANN ONCOL, 12(2), 2001, pp. 179-182
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma
Authors: Bonetti, A Zaninelli, M Leone, R Franceschi, T Fraccon, AP Pasini, F Sabbioni, R Cetto, GL Sich, D Brienza, S Howell, SB
Citation: A. Bonetti et al., Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, ANN ONCOL, 12(2), 2001, pp. 187-191
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
Authors: Bensmaine, MA Marty, M de Gramont, A Brienza, S Levi, F Ducreux, M Francois, E Gamelin, E Bleiberg, H Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients, BR J CANC, 85(4), 2001, pp. 509-517
Clinical pharmacokinetics of oxaliplatin: A critical review
Authors: Graham, MA Lockwood, GF Greenslade, D Brienza, S Bayssas, M Gamelin, E
Citation: Ma. Graham et al., Clinical pharmacokinetics of oxaliplatin: A critical review, CLIN CANC R, 6(4), 2000, pp. 1205-1218
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients
Authors: Bensmaine, MA de Gramont, A Brienza, S Marty, M Levi, F Ducreux, M Francois, E Gamelin, E Bleiberg, H Bleuzen, P Simon, J Cvitkovic, E
Citation: Ma. Bensmaine et al., Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients, EUR J CANC, 36(18), 2000, pp. 2335-2343
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancerpatients
Authors: Garufi, C Brienza, S Pugliese, P Aschelter, AM Bensmaine, MA Bertheault-Cvitkovic, F Nistico, C Giunta, S Caterino, M Giannarelli, D Cosimelli, M Levi, F Terzoli, E
Citation: C. Garufi et al., Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancerpatients, ANTI-CANC D, 11(6), 2000, pp. 495-501
Immunohemolytic anemia following oxaliplatin administration
Authors: Garufi, C Vaglio, S Brienza, S Conti, L D'Attino, RM Girelli, G Terzoli, E
Citation: C. Garufi et al., Immunohemolytic anemia following oxaliplatin administration, ANN ONCOL, 11(4), 2000, pp. 497-497
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function
Authors: Massari, C Brienza, S Rotarski, M Gastiaburu, J Misset, JL Cupissol, D Alafaci, E Dutertre-Catella, H Bastian, G
Citation: C. Massari et al., Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function, CANC CHEMOT, 45(2), 2000, pp. 157-164
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery
Authors: Giacchetti, S Itzhaki, M Gruia, G Adam, R Zidani, R Kunstlinger, F Brienza, S Alafaci, E Bertheault-Cvitkovic, F Jasmin, C Reynes, M Bismuth, H Misset, JL Levi, F
Citation: S. Giacchetti et al., Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery, ANN ONCOL, 10(6), 1999, pp. 663-669
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory recurrent non-Hodgkin's lymphoma patients
Authors: Germann, N Brienza, S Rotarski, M Emile, JF Di Palma, M Musset, M Reynes, M Soulie, P Cvitkovic, E Misset, JL
Citation: N. Germann et al., Preliminary results on the activity of oxaliplatin (L-OHP) in refractory recurrent non-Hodgkin's lymphoma patients, ANN ONCOL, 10(3), 1999, pp. 351-354
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program
Authors: Brienza, S Bensmaine, MA Soulie, P Louvet, C Gamelin, E Francois, E Ducreux, M Marty, M Andre, T de Braud, F Bleiberg, H Segal, V Itzhaki, M Cvitkovic, E
Citation: S. Brienza et al., Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program, ANN ONCOL, 10(11), 1999, pp. 1311-1316
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma
Authors: Levi, F Zidani, R Brienza, S Dogliotti, L Perpoint, B Rotarski, M Letourneau, Y Llory, JF Chollet, P Le Rol, A Focan, C
Citation: F. Levi et al., A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma, CANCER, 85(12), 1999, pp. 2532-2540
Risultati: 1-12 |